Guideline Video

Guideline Resources

  • Clinically Localized Prostate Cancer
  • American Urological Association/American Society for Radiation Oncology
  • April 16th, 2026
  • Summary
  • Full-text

Video Transcription

Just published April 16th, 2026, the American Urological Association and American Society for Radiation Oncology’s newest guideline update on Clinically Localized Prostate Cancer.

This 2026 update integrates newly published literature related to the evaluation and management of clinically localized prostate cancer. The recommendations provide a framework to facilitate clinical decision making across risk stratification, staging, management, and follow-up care.

In today’s rapid update, we’ll just be going over a summary of new and updated recommendations so for the full guideline, make sure to check it out on guidelinecentral.com.

Let’s get started. 

Starting with the section on Staging

  • The guideline states that prostate MRI may be used to guide surveillance biopsies, evaluate location and extent of prostate disease, and assist with treatment planning. 
  • For asymptomatic patients with prostate cancer that is low- or favorable intermediate-risk, clinicians should not regularly perform nodal or metastatic staging bone scans, cross-sectional imaging, or prostate-specific membrane antigen positron emission tomography (PSMA PET) scan. 
  • For staging of unfavorable intermediate- and high- risk localized prostate cancer, clinicians should use either a combination of cross-sectional imaging and bone scan, or PSMA PET.
  • For the evaluation of metastases, clinicians may consider using PSMA PET for patients with unfavorable intermediate and high- risk localized prostate cancer with negative conventional imaging. 

Next the section on Risk-Based Management

  • For patients with low- and intermediate-risk prostate cancer, clinicians should inform patients that focal or whole gland ablation is still considered investigational.

And last the section on Principles of Radiation

  • Androgen deprivation therapy (ADT) may be initiated concurrently or neoadjuvantly when combined ADT and radiation are utilized. 
  • For select patients with high-risk localized or locally advanced prostate cancer undergoing radiation therapy, clinicians should combine androgen deprivation therapy with abiraterone acetate and prednisone for 24 months.

And there you have it. Make sure to check out the full guideline from the American Urological Association and American Society for Radiation Oncology and other related clinical decision support tools at guidelinecentral.com.

Sign up for alerts and stay informed on the latest published articles and guidelines.